Status and phase
Conditions
Treatments
About
Manifold data revealed that young breast cancer patients are characterized by aggressive clinical history. The purpose of this study is to evaluate the efficacy and safety of different strategies incorporating paclitaxel to anthracycline-based regimens in young breast cancer patients.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Female patients, age 18~40
Unilateral, operable, histologically confirmed adenocarcinoma of the breast
Stage I-III
Primary surgery with clear margins plus axillary dissection
Able to start protocol Rx within 8 weeks of surgery
Histological or cytological confirmation of estrogen-receptor positive (ER+) breast cancer: the immunohistochemical cut-off for ER positive status was
1% or more staining in nuclei
HER-2 negative (IHC 0,1+ or 2+ with a negative in situ hybridization test by chemotherapy
pathologically confirmed regional node-positive disease, or node-negative disease with high-risk factors (primary tumor diameter >10 mm when histological grade III, or tumor diameter >20 mm when histological grade II)
ECOG performance status 0-1
Adequate cardiac, renal, hepatic and hematologic function
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
521 participants in 2 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal